Liver transplants are not often rejected in patients weaned from immunosuppression and are spontaneously accepted in some animal models. We review past and recent findings of liver transplantation and propose a unified model in which several mechanisms act in concert to induce and maintain tolerance in both naïve and effector T cell compartments. First, passenger leukocytes migrate to lymphoid tissues and induce apoptosis of alloreactive naïve T cells. Second, antigen-specific activation and subsequent deletion of naïve and effector cells within the liver itself purge the repertoire of alloreactive T cells. Other mechanisms such as microchimerism and migration of donor dendritic cells to the thymus may play a predominant role in maintaining tolerance, and soluble major histocompatibility complex molecules, donor peptides, and regulatory T cells may participate in the induction and maintenance phases. Thus, the major challenge in liver transplantation will be to favor these tolerogenic processes while developing strategies that specifically inhibit alloreactive memory T cells.
The ability of the immune system to discriminate between self and nonself is essential to eradicate pathogens but represents a real challenge for the treatment of autoimmunity and the transplantation of solid organs. In transplantation, the long-term solution is either to transplant a new organ generated from the patient's own stem cells or to deceive the immune system into recognizing a ''nonself'' organ as ''self'' without affecting its ability to respond to foreign molecules and microbes. The first possibility is unlikely to be realized in clinical practice for several years. Therefore, at present, patients with end-stage organ failure still require organ transplantation when all other therapies have failed. Unless the patient and donor are identical twins or the recipient receives immunosuppressive therapy, organ transplants are rejected by the host immune system within 1 or 2 weeks. Since the introduction of cyclosporin A (CsA) in 1978, allograft survival has improved remarkably. 1 However, all immunosuppressive drugs currently used in organ transplantation can be directly toxic or induce general immune suppression, or both, allowing opportunistic infections or cancer to develop. Furthermore, although modern immunosuppressive drugs are effective in preventing acute rejection, most transplanted solid organs still undergo chronic immune-mediated damage, which may result in gradual dysfunction and eventual loss of the graft.
Liver allografts are unique in solid organ transplantation as they are spontaneously accepted indefinitely in some species across totally major histocompatibility complex (MHC) incompatible barriers. [2] [3] [4] In addition, liver transplants induce donor-specific tolerance in otherwise immune-competent recipients. 3, 4 Although these remarkable properties were described many years ago, mechanisms responsible for the ''liver tolerance effect'' remain obscure. 5 The understanding of these mechanisms would represent a major breakthrough in transplantation immunology as it could be beneficially applied to prevent rejection of liver and other solid organ transplants in humans. In this review on liver transplantation, we engage the special properties that set the liver apart from other solid organs. We describe the immune events during the acute rejection of most solid organs and the different mechanisms proposed for spontaneous liver allograft acceptance and tolerance. Finally, we attempt to integrate the mechanistic concepts into a unified model of liver transplantation tolerance.
ASPECTS OF ACUTE ALLOGRAFT REJECTION IN THE ABSENCE OF IMMUNOSUPPRESSION

Ischemia-Reperfusion Injury and the Innate Immune Response
Cold and warm ischemia 6, 7 and surgical handling 8 during organ retrieval and implantation cause direct cellular damage of the graft. Cell debris, disruption of the endothelial layer during reperfusion, and the release of proinflammatory cytokines and chemokines by damaged cells attract blood monocytes and neutrophils, which infiltrate the transplanted liver. 9 Monocytes differentiate into macrophages and dendritic cells (DCs), and both cell types rapidly engulf and process donor liver antigens. DCs are known as professional antigen-presenting cells (APCs). Their main function is to activate T cells and amplify the local immune response and inflammation by secretion of cytokines and chemokines. 10 The role of macrophages and neutrophils is primarily that of phagocytosis of cell debris and the release of large amounts of reactive oxygen species that favor host defense against pathogens. In the setting of transplantation, however, these toxic mediators further damage the graft. 9 This damage caused by ischemia, surgical trauma, macrophages, and neutrophils is referred to as ischemia-reperfusion injury (IRI) and occurs equally in both syngeneic and allogeneic grafts. Although initially nonspecific, IRI has a direct effect on allograft survival 11 as it decreases the regenerative capacity of the organ and influences the adaptive immune response. 12, 13 Alloreactive Host Antibodies Preexisting antibodies directed against antigens of the ABO blood group and, to a lesser extent, against the highly polymorphic MHC are the mediators of hyperacute allorejection, which occurs within hours after reperfusion.
14 Their binding to surface antigens results in cell death mediated by phagocytes and natural killer (NK) cells or direct cell lysis through complement binding. In the clinical setting, hyperacute rejection mediated by preformed antibodies is rarely seen as donors and recipients are matched for ABO blood groups, and transplantation in the presence of a positive cross-match (existence of donor-specific antibodies) is avoided. However, newly generated antibodies against the graft are increasingly recognized as mediators of severe acute rejection, which is often refractory to immunosuppressive therapy that primarily targets T cells rather than B cells. 15 The T Cell Immune Response Early experiments performed by Medawar and colleagues have established that acute allograft rejection is mediated by the adaptive immune system as it is antigen specific and induces memory. 16 The critical role of T cells in allograft rejection was confirmed in later studies showing that kidney allografts were indefinitely accepted in athymic nude rats that lacked T cells and the adoptive transfer of T cells was sufficient to cause acute rejection. 17 Antigen-specific damage of the allograft involves both direct allograft recognition by preexisting memory T cells and activation of naïve and memory T cells through direct and indirect antigen presentation within recipient secondary lymphoid tissue (SLT) consisting of lymph nodes (LNs) and the spleen.
GRAFT RECOGNITION BY NAI¨VE, EFFECTOR, AND MEMORY T CELLS
The relative contributions of naïve, effector, and memory T cells to allograft rejection are still unclear. It is suggested that the trafficking pathways of these T cell subsets are different and that this would affect their respective behavior during transplantation. Naïve T cells, which lack adhesion molecules and chemokine receptors required to enter peripheral tissues, 18 are precluded from recognizing donor peptide/MHC complexes expressed by the allograft. Instead, naïve T cells recirculate via blood and lymph through SLT, and it is here that they encounter donor antigens presented by DCs. The requirement of SLT for the activation of naïve T cells during cardiac allograft rejection has been formally demonstrated using aly/aly mice that have a defect in the proper formation of LNs. When these mutant mice were splenectomized, they failed to recognize (ignored) heart allografts, which were accepted indefinitely. 19 However, the adoptive transfer of T cells from aly/aly mice into wild-type syngeneic mice that had received a cardiac allograft led to their effective activation, proliferation, and differentiation into effector T cells that left the lymphoid tissue and homed to the graft, where they promoted allograft rejection. 19 When naïve T cells are activated, they become large effector cells. Memory T cells are defined as cells remaining when the initial antigen stimulus has disappeared. They are usually smaller than effector cells but express an activated phenotype. 20 It is unclear whether memory T cells originate from a subset of activated cells surviving the contraction of the immune response or from the programming of some cells during primary T cell activation. Effector/memory T cells have a lower activation threshold than naïve T cells and their functional response is more immediate, [21] [22] [23] as illustrated by the accelerated rejection of allografts in presensitized animals (4 to 5 days versus 8 to 12 days in naïve recipients). 24 Memory T cells can be divided into two subsets that differ in their homing properties. 20 The central memory T cells (T CM ), like naïve T cells, express high levels of CCR7 and CD62L, two receptors that allow them to enter LNs. The effector memory T cell (T EM ) subset express variable levels of CD62L but lack CCR7 and thus do not recirculate to LNs. T EM are able to enter peripheral tissues and can directly interact with donor cells in the graft. 20 It has been estimated that 0.1% to 10% of host T cells are specific for alloantigens. [25] [26] [27] [28] Two major factors contribute to the remarkably high percentage of graft-specific T cells in a non-presensitized recipient. First, T cell activation within LN is mediated by both donor and host APCs. Second, in addition to naïve T cells, preexisting cross-reactive T EM and effector T cells can directly recognize the graft in the periphery (Fig. 1) .
ANTIGEN PRESENTATION BY DCS IN SECONDARY LYMPHOID TISSUES
Naïve T cells and T CM can be activated by donor DCs by the ''direct presentation pathway'' or by recipient DCs by the ''indirect presentation pathway'' (see also review by Martinez and Rosen 29 ). The direct presentation pathway refers to the allorecognition by the recipient T cell receptor (TCR) of donor MHC molecule/donor peptide complexes expressed on graft cells and passenger leukocytes. Depending on whether MHC class I or class II molecules are recognized, this results in the activation of either CD8 þ or CD4 þ T cells. The indirect presentation pathway refers to the recognition of recipient MHC molecule/donor peptide complexes by the recipient TCR. This pathway represents the conventional pathway used by the immune system when confronted with pathogens. It is mediated by host APCs that capture alloantigens and present donor allopeptides in association with either recipient class I or class II MHC molecules to CD8 þ or CD4 þ T cells, respectively. Alloantigen presentation by recipient MHC class II molecules is thought to be triggered by most types of DCs, whereas alloantigen presentation by recipient MHC class I molecules is mediated only by a specialized subset of DCs 30 and liver sinusoidal endothelial cells (LSECs), 31 a process referred to as crosspresentation (presentation of exogenous antigen by MHC class I molecules). Alloreactive T cells activated by the indirect presentation pathway recognize peptides that are not conserved among individuals. These variations might result from allelic differences either in the polymorphic residues of the MHC molecules themselves 32 or other functional proteins of the cell, expressed as ''minor transplantation antigens.''
The relative contribution of the direct versus the indirect presentation pathway in allograft rejection is undecided. The indirect presentation pathway should play a minor role in rejection as T cells activated by recipient APCs would recognize the transplant only if their TCRs were to cross-react with donor MHC molecules. 33 In fact, several studies suggest that the direct presentation pathway is the predominant pathway involved in acute rejection as it recruits a high percentage of alloreactive T cells, whereas T cells activated by the indirect pathway are 100-fold less frequent 34 and are thought to be mainly involved in chronic rejection. 35 Moreover, and consistent with a predominant role for the direct presentation pathway in rejection, donor APCs were shown to induce a stronger allo-T cell response when presenting donor antigens in primary in vitro mixed lymphocyte reactions (MLR) than recipient APCs. 32 In the transplant setting, some findings favor a predominant role of the direct presentation pathway in allograft rejection. 36 When donor DCs were depleted by parking the kidney shaft in a tolerized recipient rat, the transplant was ignored by host T cells. 37 Immunogenicity could be restored with ensuing rapid rejection of the graft by the intravenous injection of donor DCs. As still further evidence for the important role of donor DCs in allograft rejection, there are observations in a rat heart transplant model in which donor DCs were found in close contact with host T cells within the recipient's spleen, 38 demonstrating colocalization of donor DCs with host T cells. Although these studies showed that donor DCs can play a critical role in graft rejection, depletion of donor leukocytes did not always induce a state of antigenic ignorance and allograft acceptance [39] [40] [41] [42] ; accordingly, rejection can also be mediated by the indirect presentation pathway.
T cell activation by both the direct and indirect pathways can be reduced by matching MHC molecules between donors and recipients. The general importance of this practice is illustrated by the strong correlation of mismatched human leukocyte antigen (HLA) molecules and the frequency of acute and chronic rejections in renal and cardiac transplantation, 43 but, as cited later, the liver is an exception here.
DIRECT RECOGNITION OF THE GRAFT BY CROSS-REACTING EFFECTOR/MEMORY T CELLS
Both T EM and recently activated T cells are capable of entering peripheral tissues and recognizing alloantigens independently of professional APCs and SLT. Activated allospecific T cells adoptively transferred into splenectomized aly/aly mice receiving a heart allograft resulted in rejection, 19 confirming that effector T cells can act in the complete absence of SLT. Alloreactive T EM , present at the time of transplantation, might be due to previous contact with foreign antigens, whether during pregnancy, blood transfusions, or previous viral infections by molecular mimicry. 22, 44 The TCR can display a high level of cross-reactivity, 33 and this has been confirmed to occur between viral epitopes and allograft antigens in both experimental animals 45 and humans. 46 As the frequency of memory T cells increases with infections and age 47, 48 it is not surprising that protocols established in young, naïve, and otherwise healthy rodents have failed to induce tolerance in antigen-experienced primates and humans. 21 In humans, the presence of alloreactive T EM is particularly seen as a major obstacle for future therapies in solid organ transplantation.
49-51
THE LIVER TOLERANCE EFFECT IN TRANSPLANTATION
Liver Transplantation in Experimental Animal Models
In 1969, Calne and colleagues reported that English outbred pigs spontaneously accepted liver allografts indefinitely without any immunosuppressive treatment. 2 This finding has been confirmed in wild mice 52 as well as in many mouse and rat inbred strains combinations. 4, [53] [54] [55] Recipients of liver grafts also accepted subsequent skin or heart transplants from the same donor strain while rejecting third-party grafts. 4, [53] [54] [55] These experiments formally demonstrated that the liver, in addition to being spontaneously accepted, could induce donor strain specific tolerance to subsequent transplants of THE LIVER AND TRANSPLANTATION TOLERANCE/BENSELER ET AL other tissues. In addition, acting like an immunosuppressive drug, a liver transplant was able to reverse severe ongoing graft rejection of a previous organ transplant from the same donor strain including heart, 56 pancreas, 57 and skin. 4, 58 Liver Transplantation in Humans HUMAN LIVERS ARE MORE TOLEROGENIC THAN OTHER
SOLID ORGAN TRANSPLANTS
The so-called liver tolerance effect is not exclusive to experimental animals. Human liver allografts require less immunosuppression than other organs, 59 and, unlike the case of renal transplants, early rejection episodes do not affect long-term graft survival. 60 In 1993, Starzl and colleagues reported stable graft function in liver transplant patients who had deliberately stopped immunosuppressive treatment, 61 a condition termed operational tolerance. Since then, successful weaning from immunosuppressive therapy, either intentional or forced by lymphoproliferative disorders or life-threatening infections, has frequently been reported, albeit only in a small subset of patients. [62] [63] [64] [65] Although different indices have been proposed to be associated with successful weaning, none has been formally identified. 62 As observed in experimental models, human liver allografts seem to confer protection against rejection of other organs such as kidney, [66] [67] [68] lung, 69 and, in pediatric patients, possibly small intestine. 70 These transplants showed fewer rejections and better survival when they were combined with a liver graft.
ABO AND HLA MATCHING IN CLINICAL LIVER TRANSPLANTATION
In humans, hyperacute rejection mediated by preformed antibodies is a feared complication in renal transplantation but is hardly seen in liver transplantation, even across ABO blood groups or in the presence of cytotoxic antibodies against donor cells (positive cross-match). In children the requirement for ABO matching remains controversial, 71, 72 but in adults transplantation of an ABO mismatched liver significantly impairs survival. 73 In addition, preformed antibodies appear to mediate rejection, especially a high titer of lymphocytotoxic anti-donor immunoglobulin G. 74 Although a crossmatch is not routinely performed in liver transplantation, there are reports that a positive cross-match can become negative within a few hours after transplantation without affecting the graft. 67, [74] [75] [76] Likewise, although HLA matching between donor and recipient plays an important role in preventing acute and chronic rejection of other grafted tissues, mismatches have no effect on the overall long-term survival of liver allografts in adults 43, 77 or children. 78, 79 The dictum does hold that ''T cell mediated alloresponses are not important in human liver allografts'' 5 but this might be influenced by the underlying disease that caused liver failure. A study that examined the effect of HLA matching in liver transplants for hepatitis C revealed that the overall survival of the liver allograft was the same regardless of the HLA matching but liver damage depended on two different events: more allograft rejection in the mismatched group and faster progression of hepatitis C in the HLA matched group. 80 
CURRENT IMMUNOSUPPRESSIVE TREATMENTS IN CLINICAL LIVER TRANSPLANTATION
Immunosuppression of liver transplant recipients is determined by factors such as the etiology of the patient's liver disease, coexisting illnesses, drug toxicity, and distinct effectiveness of drugs in preventing allograft rejection. 59, 81 However, most protocols include an induction therapy consisting of high-dose corticosteroids and a calcineurin inhibitor (CI), such as CsA, with or without mycophenolate mofetil (MMF), azathioprine, sirolimus, and/or antibodies that either deplete T cells or block interleukin 2 (IL-2) and costimulatory signaling. Although these protocols effectively prevent acute allograft rejection by blocking T cell activation, proliferation, or effector function, they may concurrently interfere with the tolerogenic properties of liver grafts by inhibiting peripheral deletion of alloreactive T cells or preventing the induction of T cell anergy and regulatory cells (see later).
It is not the purpose of this review to describe the molecular mechanisms, but the effect of some drugs on the spontaneous acceptance of liver allografts has been studied in rats. A 4-day course of methylprednisolone either given directly or delayed after liver transplantation converted indefinite liver graft survival to rejection occurring 70 to 80 days after transplantation. 82 However, in another strain combination that usually rejects the liver within 2 weeks, the same course could protect the graft, which then survived for over 40 days. 82 Although both CsA and MMF did not influence spontaneous acceptance of liver allografts, they were able to induce long-term acceptance of normally rejected livers. 83, 84 The tolerogenic effect of CsA was more pronounced when its administration was delayed as shown in a heart transplant model. The combination of a single injection of donor splenocytes with CsA given from day 0 only prolonged graft survival, whereas delayed administration of CsA induced indefinite survival. 85, 86 This has led to clinical trials, and a recent study has confirmed the safety of delayed administration of CI in children. 87 However, the efficacy of this treatment in prolonging long-term survival in human liver transplantation needs further validation. Other drugs such as sirolimus or azathioprine and the effect of combining several drugs have not yet been tested in animal models of spontaneous allograft tolerance.
In summary, although immunosuppressive therapy effectively prevents acute rejection, protocols are empirical and might interfere with the induction of tolerance. Thus, understanding mechanisms of spontaneous liver allograft acceptance would allow the design of more effective protocols.
PROPOSED MECHANISMS FOR LIVER TRANSPLANT TOLERANCE
It has been clearly established experimentally, that ''spontaneous'' liver tolerance is not attributable to antigenic ignorance but rather to an active process involving T cell activation, proliferation, and infiltration of the allograft. 88 This concept correlates with findings in human liver transplantation, where an early lymphocytic infiltrate is not necessarily associated with rejection. 89 Several nonexclusive mechanisms have been proposed to explain the remarkable property of liver grafts to induce donor-specific tolerance.
Role of Soluble Donor MHC Class I Molecules
Liver transplants release large amounts of soluble MHC class I molecules, 90 so raising the hypothesis that soluble MHC might be responsible for donor-specific tolerance. Indeed, when secretion of soluble donor MHC class I was increased either by injecting genetically modified hepatocytes or by using MHC class I-encoding adenoviruses, the survival of liver 91 and heart 92 allografts undergoing rejection was prolonged. However, the effect of soluble MHC was challenged by experiments showing that the livers of mice that were MHC class I deficient because of b 2 -microglobulin gene knockout were not rejected by allogeneic wild-type mice. 93 Yet, this study was not definitive as these mice lacked cell surface as well as soluble MHC class I molecules. Thus, in the absence of their ligand, it would be expected that T cells were unable to recognize the graft and would have therefore ignored donor cells.
Soluble MHC might induce tolerance by binding directly to alloreactive antibodies. 54, 94 This could explain why livers can be transplanted without major alloimmune-mediated injury in the presence of preformed antibodies. It has also been reported that soluble MHC might interact directly with the TCR and induce apoptosis of alloreactive T cells. 95 However, as interactions between TCRs and soluble MHC-peptide complexes tend to be unstable and prone to rapid dissociation, 96 the importance of this mechanism remains uncertain. Alternatively, soluble MHC molecules may be a source of donor peptides and capable of inducing tolerance following processing and presentation of such peptides to recipient T cells by immature (and hence inherently tolerogenic) host DCs. 97, 98 Consistent with this concept, injection of soluble donor MHC bound to a monoclonal antibody, so as to increase the uptake of allo-MHC by macrophages and DCs, did prolong allograft survival more than infusion of soluble donor MHC alone. 99 However, although the administration of soluble MHC does prolong allograft survival, this treatment has never been shown to induce long-term tolerance of an allograft.
Tolerance Induced by Passenger Migratory Donor Cells
In humans, multiple blood transfusions prior to transplantation (''blood transfusion effect'') 100 enhance survival of an allograft, and this is mirrored in animal models by a single perioperative infusion of donor splenocytes. 101, 102 These findings, and the presence of long-term donor cell chimerism in patients completely weaned from all immunosuppressive drugs, 103 led to the concept that passenger donor cells are critical for transplantation tolerance.
Solid organ transplants consist of tissue cells (essentially parenchymal and endothelial cells) and nonparenchymal cells that include hematopoietic stem cells and passenger leukocytes. Although ''passenger leukocytes'' are often regarded as cells leaving the transplanted organ, it is important to note that, in the case of the liver, some leukocyte subsets such as Kupffer cells (KCs), which are liver-resident macrophages, have not been reported to recirculate. Donor cell chimerism, reflecting the emigration of passenger leukocytes through the blood into recipient lymphoid tissues, is frequently observed after solid organ transplantation 104 ; donor cells including DCs, T cells, and B cells are often found within SLTs, 38, 105 and hematopoietic stem cells home to the recipient bone marrow, where they can give rise to donor-derived cells including DCs and T cells. 106 Two major concepts have been proposed to explain how donor migratory cells can induce tolerance. These are ''inappropriate activation of host T cells within the lymphoid tissues,'' which results in death by neglect, 107 and ''long-term donor cell microchimerism,'' which is believed to antagonize alloreactive host T cells. 108 Both concepts rely on liver transplant tolerance being exclusively mediated by passenger cells that emigrate from the graft regardless of the organ's architecture. According to these hypotheses, the liver would be more likely to induce tolerance because of its large size 109 or a high number of migratory donor cells, or both. Consequently, tolerance would be transferable to other solid organs and could be promoted by increasing the number of migratory donor cells or by enhancing the establishment of long-term microchimerism.
INAPPROPRIATE ACTIVATION OF HOST T CELLS WITHIN THE LYMPHOID TISSUE
Experimentally, in rats, the depletion of donor leukocytes by irradiation of the donor before liver transplantation THE LIVER AND TRANSPLANTATION TOLERANCE/BENSELER ET AL was able to break spontaneous liver tolerance 42, [110] [111] [112] ; tolerance could be restored by adoptive transfer of donor leukocytes purified from liver or spleen 113 or by parking the irradiated liver grafts in animals from the donor strain for 36 hours to allow repopulation with donor leukocytes. The tolerogenic properties of donor leukocytes were further confirmed in other solid organ transplant models in which the adoptive transfer of donor splenocytes at the time of transplantation was able to prolong heart allograft survival 86 and to induce tolerance of kidney and liver allografts that were otherwise rejected. 102 The ''high-dose tolerance effect'' suggests that the amount of tissue grafted is an important determinant in graft survival. 109 However, whether one or more organs were transplanted at the same time, all were chronically rejected: indefinite survival required the injection of donor splenocytes. 113 Thus, donor leukocytes were more critical for tolerance induction than the amount of grafted tissue.
To elucidate further the mechanisms of tolerance induced by donor leukocytes, the cellular and molecular events that occur after transplantation were compared between two rat models of spontaneous allograft acceptance and rejection. The preceding experiments showed a slight increase in CD4 þ , CD8
þ , CD11b/c, and B cell infiltrates within tolerated liver allografts on day 3 after transplantation, although only the increase in B cells was statistically significant. 114 Interestingly, there were no differences in donor cell numbers in the liver-draining celiac LN and the spleen on day 1, but tolerant animals displayed a 5-to 10-fold increase in IL-2 and interferon g (IFN-g) messenger RNA (mRNA) 105 and a high number of apoptotic leukocytes within the spleen and liver graft on day 3. 115 This work led to the conclusion that liver tolerance was indeed an active process mediated by donor leukocytes in the recipient SLT, where such leukocytes induced an early activation of host T cells that eventually resulted in death by neglect related to an insufficient supply of survival cytokines. 107 Although these studies provide convincing evidence that donor leukocytes are able to induce tolerance, it remains to be proved whether the tolerogenic effect does actually occur within SLT. Depletion of donor leukocytes diminished levels of both IL-2 and IFN-g mRNA within recipient spleens and converted liver tolerance into rejection, but mRNA levels for both cytokines remained high within the liver-draining LNs, 105 indicating that the findings in LNs were not associated with migratory donor cells.
The nature of the cellular subset required for passenger leukocyte-induced allograft survival also remains unclear. Some studies have implicated the T cell 101, 110, 113 or the B cell subset 102, 116 and others the DCs. 117 However, regardless of the cellular type or underlying mechanisms, it is notable that experiments involving the adoptive transfer of donor leukocytes with other solid organ transplants have induced prolonged allograft survival rather than long-term tolerance, 85, 86 an effect comparable to that of soluble MHC. Thus, although passenger leukocytes may play a role in tolerance associated with liver transplantation, they seem not to be solely responsible for this effect.
LONG-TERM DONOR CELL MICROCHIMERISM
Donor cell chimerism refers to the persistence of donor hematopoietic cells in the recipient following transplantation. After its first description in 1969, 118 Starzl et al reported in 1992 that donor cell chimerism was often observed at low frequency (less than 1%) in long-term surviving liver transplant patients. 119 They proposed that this ''microchimerism'' was entirely responsible for liver graft acceptance. 103 Driven by the fact that solid organ transplants rich in lymphoid tissue usually do not elicit a graft-versus-host disease (GvHD), Starzl et al proposed that the outcome of liver transplants is determined by a limited graft-versus-host (GvH) and host-versus-graft (HvG) response. 61 When balance in this ''two-way MLR'' is reached, the graft is accepted but otherwise rejection or GvHD would ensue. According to this model, both reactions would stabilize over months; immunosuppressive treatment could be decreased and, when reactions were in perfect balance, even completely stopped. 108 Since the first description in 1992 of the Starzl theory, the relevance of sustained donor cell chimerism after solid transplantation has been intensively studied and debated. [120] [121] [122] [123] [124] [125] Among major issues is whether donor cell chimerism is the cause or the consequence of tolerance. 126 In human transplantation, long-term microchimerism is frequently observed but it neither correlates with the integrity state of the graft 123, 125, 127 nor identifies patients suitable for successful weaning of immunosuppressive therapy. 120, 121 In addition, microchimerism can frequently be observed in recipients of other solid organs [128] [129] [130] that are not regarded as being intrinsically tolerogenic.
In an experimental model of CsA-induced heart tolerance, the deletion of donor leukocytes on day 0 converted acceptance into chronic rejection but the same deletion protocol on day 18 did not affect tolerance. 124 Complete deletion of donor leukocytes outside the graft was confirmed by immunohistochemistry, but donorspecific DNA sequences were still detectable in the liver and spleen using a polymerase chain reaction (PCR) technique. 124 This finding was confirmed by others. 131 It is not clear whether these results indicate the presence of residual donor cells or, alternatively, donor DNA released by the allograft. Furthermore, positive PCR results did not correlate with tolerance. 124 The conclusion would be that donor leukocytes are important in the induction phase of allograft tolerance, but long-term microchimerism may not to be essential for sustained graft acceptance. 122, 132 The Zinkernagel laboratory 133 now suggests that microchimerism is in fact required to maintain tolerance. A single injection of splenocytes expressing a single foreign MHC class I restricted epitope of the lymphocytic choriomeningitis virus (LCMV) was sufficient to confer long-term microchimerism in recipient mice; such mice became unresponsive to this epitope upon challenge with LCMV, even when thymectomized, indicating that tolerance was not induced by central deletion in the thymus. When microchimerism was abrogated by the adoptive transfer of primed allogeneic cytotoxic T lymphocytes (CTLs) specific for the epitope, only mice with a functional thymus were able to restore host T cell responsiveness 42 days later. This suggested that alloreactive T cells were newly generated and that hyporesponsiveness was due to peripheral deletion. 133 Although this study addressed a very important question, it did not exclude the remote possibility that the restoration of alloresponsiveness was at least partially mediated by the cytolytic action of the same alloepitope specific CTLs used to abrogate microchimerism. Moreover, in a previous study using this model, the same authors had shown that the administration of the allopeptide alone, independently of spleen cells, was able to induce transient hyporesponsiveness. 134 In this model, it therefore remains unclear whether microchimerism induces tolerance by directly killing alloreactive host T cells or by providing a constant source of donor antigen that eventually leads to T cell clonal exhaustion and tolerance.
If microchimerism were to act by causing a contemporaneous GvH and HvG response as proposed by Starzl, it is unclear how this might lead to peripheral tolerance. GvHD is usually mediated by donor T cells that recognize recipient MHC/peptide complexes and primarily damages the skin, liver, and gut, but such damage has not been described in liver-transplanted patients completely weaned from immunosuppression (operational tolerance). However, donor T cells participate in chimerism and these can either be newly generated from hematopoietic stem cells that are abundant in the liver 106 or be transplanted as mature T cells. Although microchimerism persisting over years indicates that self-renewing hematopoiesis of donor cells does occur after solid organ transplantation, newly generated donor T cells are unlikely to play a role in the induction phase of liver transplant tolerance as their maturation requires several weeks. In addition, unless they function as veto cells, negative selection in the host thymus would delete donor T cell clones reactive against recipient MHC/recipient peptide. It is therefore likely that tolerance induced by GvHD would be mediated by crossreacting mature donor T cells transplanted with the graft itself. Indeed, studies using splenocyte injections to prolong allograft survival indicate that the T cell component confers the tolerogenic effect of donor leukocytes in heart 101 and liver 110, 113 transplant models. Whether as suggested 108 these T cells act by an ongoing GvH reaction is uncertain because the mature donor T cells initially transferred with the graft would need to survive indefinitely to sustain allograft acceptance. Finally, we note that despite evidence for tolerance being induced by mature donor T cells, the infusion of donor bone marrow in liver transplant recipients can actually lead to severe GvHD rather than tolerance. 135 Role of Tolerogenic Liver DCs DCs are the most potent among various APCs responsible for the initiation of immune responses. 136 More recently, DCs have proved important in the induction/ maintenance of tolerance. 98, 117 Thus, antigen presentation by immature DC subsets that do not provide proper costimulatory signals is tolerogenic. In addition, secretion of cytokines such as IL-10 and transforming growth factor b (TGF-b) by DCs can inhibit T cell proliferation, inducing anergy of both naïve and activated CD8 þ T cells, 137 and cause the generation of regulatory T cells (Tregs). [138] [139] [140] The recent description of plasmacytoid DCs, a DC subset with potential regulatory activity that secretes high levels of IFN-a, adds an attractive possibility that such APCs might be specialized in the regulation of the T cell response. Indeed, a recent report has implicated alloantigen-presenting plasmacytoid DCs as playing a role in the induction of tolerance to cardiac allografts. 141 The total number of DCs in a normal liver is up to fivefold 142 higher than in other solid organs, but the volume density is the lowest of all organs. 142 Most studies agree that freshly isolated hepatic DCs are immature and are less immunogenic than splenic DCs. 143 They express low levels of MHC class II and costimulatory molecules (CD80 and CD86), which fits with their poor allostimulatory ability in MLR assays. 143, 144 They also secrete IL-10 145 and display a higher threshold for activation than splenic DCs because of decreased expression of Toll-like receptor-4. 146 It has been proposed that hepatic DCs induce apoptosis and possess immune regulatory/suppressive functions, 147 and they might participate in the generation of Treg populations. 148, 149 However, there are data suggesting that when liver DCs do mature they are immunogenic. 150 In particular, after donor mice were injected with the fmslike tyrosine kinase 3 ligand (Flt3L), a growth and differentiation factor for DCs, liver allografts that are usually accepted were now rejected. 142 This rejection was mediated by mature DCs as it was reversible by costimulation blockade with CTLA4-Ig 151, 152 or by antibodies that neutralize IL-12, a cytokine released by activated DCs. 153 The discrepancies between conclusions from these different studies in mice might be explained by the heterogeneity of hepatic DCs. The normal mouse liver contains at least four distinct groups of CD11c þ DCs: two subsets of plasmacytoid DCs (B220 þ CD4 þ and B220 þ CD4 À ) that secrete high levels of IFN-a, one subset of myeloid DC (B220 À CD11b þ ), and one heterogeneous B220 À CD11b À subset containing both myeloid and lymphoid-related DCs. In contrast to the plasmacytoid-type DC, the two latter groups were shown to be able to induce alloresponses in an MLR. 154 The site where hepatic DCs might exert their function remains unclear. However, this knowledge is of primary importance for understanding the role of hepatic DCs in allogeneic responses, as the maturity and phenotype of DCs can change as they migrate. DCs might act in the graft itself or, following their migration, they may function extrahepatically in the draining LNs or potentially in the thymus. Several studies indicate that most hepatic DCs are located within the portal tracts rather than in liver sinusoids and hence should not have access to naïve T cells. This combination of DC localization in the portal tracts with an immature phenotype suggests that hepatic DC are unlikely to activate naïve T cells within the liver itself. However, it is unclear whether all of the various hepatic DC subsets are located within the portal tracts. Furthermore, DCs should still be able to interact with effector and memory T cells that are able to infiltrate the portal tracts. In addition, the normal hepatic microenvironment might potentiate the tolerogenic properties of hepatic DCs. Not only can hepatic DCs and other liver resident cells secrete IL-10, but the hepatic environment is also rich in TGF-b, a cytokine that inhibits antigen-dependent expansion of T cells in vivo and in vitro 117 and induces delayed apoptosis of T cells. 155 Interestingly, TGF-b is produced by hepatocytes after hepatectomy 156 and may help in the control of hepatocyte regeneration after liver damage. Thus, it is quite possible that the hepatic microenviroment is also involved in the maturation of tolerogenic DCs.
A variant of the microchimerism model suggests that DCs or DC progenitors derived from donor hematopoietic stem cells emigrate to the thymus and serve for central deletion of recipient T cells reactive against donor MHC/donor peptide. 157, 158 Consistent with this concept, allogeneic DCs can home to the recipient thymus 159 and effect negative selection. 160 Although thymic T cell deletion mediated by donor DCs explains how the generation of alloreactive T cells is prevented, it does not explain how donor cell chimerism prevents mature alloreactive T cells from mediating allograft damage. Furthermore, the thymus does not seem to play a major role in the induction of spontaneous liver tolerance, as thymectomized rats still accepted liver transplants indefinitely. 161 One of the most likely models is that IRI associated with transplantation induces maturation of DCs and promotes migration of tolerogenic hepatic DCs into SLT, where they could induce apoptosis of alloreactive T cells, 162 secrete cytokines such as TGF-b that downregulate immune responses, or encourage development of Tregs. Although such DCs are poor stimulators of allo-T cell responses, cultured immature hepatic DCs injected into allogeneic recipients induced high levels of IL-10 in SLTs, in contrast to DCs that had differentiated from the bone marrow. 163 However, other studies indicate that upon culture and antigenic stimulation, normally immature hepatic DCs can secrete IL-12 rather than IL-10 and elicit immunogenic Th1-type T cell responses that result in the production of effector cytokines such as IFN-g. 150 Although the role of hepatic DCs in inducing spontaneous tolerance to liver allografts remains speculative, several investigators have shown that human and mouse DCs manipulated ex vivo with cytokines such as IL-10, 164 TGF-b, 165 and tumor necrosis factor a 166 were able to promote antigen-specific hyporesponsiveness. Thus, manipulation of DCs could be but has not yet been used as a therapy.
Tolerance Induced by the Liver Tissue Although donor passenger leukocytes play a role in liver transplantation acceptance, some studies suggest that passenger leukocytes alone are not always sufficient to induce tolerance. Using a rat liver transplant model, Sriwatanawongsa et al 167 examined the tolerogenic potential of hepatic donor leukocytes alone and compared it with the one of liver parenchymal cells: a PVG strain liver was transplanted into a DA recipient and 20 days later, when the PVG liver was repopulated with DA leukocytes, the liver was retransplanted into a secondary PVG recipient. Although now containing passenger DA leukocytes, the transplanted liver grafts failed to induce acceptance of subsequent DA skin grafts, suggesting that passenger leukocytes alone were unable to induce tolerance. In contrast, the transplantation of a DA liver reconstituted with passenger PVG leukocytes into a PVG rat induced prolongation of subsequent DA skin grafts in the absence of passenger DA leukocytes, suggesting that parenchymal cells were able to induce tolerance. Similar experiments performed by other groups in rats 110, 112 and mice 168 confirmed these original findings.
How then do parenchymal cells lead to antigenspecific tolerance? Calne and colleagues suggested that parenchymal liver cells express high amounts of soluble MHC and this might explain their role in tolerogenesis. 167 Recent work has provided evidence that both parenchymal and endothelial cells in the liver can activate naïve T cells independently of the milieu of lymphoid tissue, and this type of activation leads to tolerance. 31, 169 In addition, it has been proposed that the liver itself is able to kill directly recently activated T cells. 5 Thus, conceivably, the liver is able to induce tolerance in both the naïve and the activated/effector T cell compartments.
PRIMARY ACTIVATION OF NAI¨VE T CELLS WITHIN THE LIVER
Immunological paradigms suggest that naïve T cells cannot enter peripheral tissues and therefore must be activated exclusively by DCs in SLTs. However, the liver is an exception to this rule, as naïve CD8 þ T cells can be activated intrahepatically without prior antigen stimulation within SLT. 170 This unique property may well be due to the particular cytoarchitecture of the liver and the associated hemodynamics (See article on the immunological milieu of the liver by Selmi et al elsewhere in this issue.) In contrast to most solid organs, the liver contains resident phagocytic cells, KCs, located within the narrow hepatic sinusoids; these cause partial luminal obstruction and sometimes even intermittent reversal of the blood flow. 171 In addition, the lack of a basement membrane and the multiple holes in LSECs, called fenestrations, allow direct contacts between hepatocytes and lymphocytes circulating through the sinusoids. Direct evidence for this type of interaction has been provided by electron microscopy and termed transendothelial hepatocytelymphocyte interaction (TEHLI). 172 The atypical hepatic architecture thus allows intimate contact between circulating lymphocytes and a variety of liver cells (Fig. 2) , such that selectins that are usually required for cells to enter peripheral tissues are dispensable in the liver. 173 Primary intrahepatic activation of CD8 þ T cells can therefore potentially be mediated by various cell types, including KCs, liver DCs, LSECs, and hepatocytes. 143 In vitro, all four cell populations have been shown to act as APCs for naïve T cells, but only LSECs 31 and hepatocytes 174 have been explored in detail; in the absence of inflammation, both cell types could induce antigen-specific T cell tolerance following intrahepatic primary T cell activation. 31, 174 Experiments performed in a transgenic mouse model where the antigen was selectively expressed in the liver on hepatocytes as well as in LNs revealed two distinct pathways of activation: whereas naïve CD8 þ T cells activated within LNs differentiated into ''competent'' and long-lived CTLs, activation by hepatocytes induced ''incompetent'' CTLs with shortened life span. 174 In vitro studies have suggested that activation induced by hepatocytes 
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resulted in death by neglect, as the incompetent T cells could be rescued by addition of IL-2. 175 Death by neglect as a mechanism of antigenspecific clonal deletion of liver-infiltrating T cells in mouse and rat liver allograft recipients has been suggested by other experiments as well. 107, 115, 176 In both models, spontaneous acceptance of a liver allograft was characterized by a high number of infiltrating T cells on day 1 followed by the accumulation of apoptotic lymphocytes on days 3 and 4, 115, 176 consistent with in vitro findings of primary activation by hepatocytes. 175 In addition, the administration of exogenous IL-2 to mice bearing spontaneously accepted liver allografts resulted in acute rejection with a lower number of apoptotic T cells within the liver. 176 In a study using liver transplants from bone marrow radiation chimeric mice, Klein and Crispe have confirmed that hepatocytes and LSECs could induce primary activation of naïve CD8
þ T cells independently of bone marrow-derived APCs (KCs and DCs). 177 However, T cells activated by hepatocytes and/or LSECs were demonstrably effective CTLs using in vivo assays, 177 thus seemingly contradicting the view that priming by hepatocytes leads to abortive activation. 174 It is possible that different results for the two models depended on the IRI-related inflammation occurring during transplantation 169 or on regulatory processes that are operative only in vivo. 177 The concluding comment is that regardless of the hepatic cell type involved in activation, one of the unique immunological properties of the liver is its ability to act as a site of primary activation of naïve CD8 þ T cells leading to death by neglect and thus purging the host T cell repertoire early after transplantation of most alloreactive T cells.
THE LIVER AS A ''KILLING FIELD'' FOR ACTIVATED T CELLS
A hepatic allograft can reverse rejection of previously transplanted organs from the same donor 4,56-58 even when transplanted up to 6 days after the initial transplant, indicating that the liver is able to induce tolerance in the recently activated T cell compartment. The observation by Crispe and coworkers that the liver accumulates numerous activated T cells undergoing apoptosis led to the conclusion that the liver is a ''graveyard'' for T cells activated in the periphery and provided a mechanistic explanation for the reversal of rejection induced by a liver allograft. 178 The initial proposal, that the liver played a non-antigen-specific role in T cell homeostasis by clearing T cells at the end of their life cycle, has since been revised, with the suggestion that the liver might actively prime and kill T cells and therefore act more as a ''killing field'' rather than a graveyard. 5, 177, 178 Both bone marrow-derived cells and liver parenchymal cells have been causally implicated in this process. 179 but neither the cell type nor the mechanisms for this killing have been identified. Several molecules may participate in this process, including galectin-1, 180 TNFR, 181 PD-L1, 182 and FasL. [183] [184] [185] Interestingly, the capacity of a transplanted liver to reverse an ongoing allograft rejection is not absolute but rather time dependent because, when heart allografts had been transplanted 6 days before same-donor liver grafts, both grafts were either accepted indefinitely in 50% of the cases or rejected at the same time. 56 In addition, animals that had been presensitized with skin transplants 14 to 20 days earlier always rejected liver grafts that would be otherwise spontaneously accepted. 93 These experiments suggest either that a transplanted liver is unable to tolerize a large number of recently activated T cells that accumulate at later time points or that it is unable to induce tolerance once a memory cell compartment has become established.
Role of Regulatory T Cells
Early studies in rats suggested that tolerance to liver grafts involves immune suppression, as splenocytes of recipients were able to suppress an allo-MLR. 186 These experiments showed that there were two spleen cell populations involved in the suppressive activity, an early-acting population enriched in macrophages that was nonspecific and mediated by prostaglandins and a late-acting population developing after 35 days that was specific and depended on T cells. Subsequent studies confirmed the presence of suppressor T cells after liver transplantation. [187] [188] [189] In some cases, specific suppression could be adoptively transferred by injecting splenocytes from the grafted recipient into irradiated new hosts. 188, 190 In recent years, the descended concept of suppressor T cells has undergone renewal and T cells with immunosuppressive function have become renamed as Tregs. The predominant Treg cell subset, initially identified by Hall et al 191 and later studied by Sakaguchi and colleagues, 192 is included among CD4 þ CD25 þ T cells and is marked by the expression of the transcription factor Foxp3. However, in addition to this subset, there is a variety of other T cell subsets with regulatory properties and varied phenotypes, including CD8
À double negative, and NK receptor expressing T cells. 193 The CD4 þ CD25 þ regulatory T cells are dividable into natural thymus-dependent Tregs and into peripherally induced Tregs that develop inter alia during an allospecific immune response. 193 Therefore, in transplantation, natural Tregs might be carried by the liver allograft or may develop as peripherally induced regulatory T cells in the recipient during the immune response against the graft.
Where and how Tregs exert their function during the induction and maintenance phases of spontaneous liver allograft tolerance are unclear, but there is evidence for their existence. T cells from naïve recipient mice or from mice that had spontaneously accepted liver allografts displayed a similar alloreactivity to donor APCs in MLRs. 194 This ''split tolerance'' between in vivo acceptance of an allograft and in vitro by MLR rejection indicates either that alloreactive T cells in vivo were unable to recognize/gain access to donor cells or that their effector function was suppressed. To discriminate between these possibilities, Dahmen et al 194 adoptively transferred leukocytes isolated from the spleen or liver from livertransplanted mice into naïve recipients. There was prolonged donor-specific survival of subsequent skin transplants, a finding confirmed by others. Adoptive transfer of splenocytes from a recipient rat bearing a donor liver for 60 days into another recipient rat resulted in prolonged survival of normally rejected skin, 195 heart, 196 or irradiated liver allografts. 197 This ''infectious tolerance'' was less effective when splenocytes from day 30 rather than day 60 liver tolerant recipients were used, 196, 197 suggesting that the regulatory cells in the splenocyte inoculum needed time to develop and that these cells were important in maintaining liver-induced donor-specific tolerance. A recent study addressed the question of the specific role of the CD4 þ CD25 þ Treg subset in spontaneous liver tolerance in mice, using a CD25 depleting antibody. 198 Liver acceptance was not affected when CD25 þ cells were depleted in the donor prior to or in the recipient 20 days after the transplantation; however, the antibody injected into recipient mice at the time of transplantation resulted in liver rejection. Therefore, CD25 þ and, presumably CD4 þ , Tregs seem to be necessary in the induction but not the maintenance phase of allogeneic tolerance in this model. This finding has been indirectly confirmed in humans among whom peripheral blood CD4 þ T cells completely weaned from immunosuppression displayed donor-specific hyporesponsiveness in vitro, which was not affected when the CD25 þ subset was depleted. 199 However Demirkiran et al 200 reported a drop in CD4 þ CD25 þ T cells in peripheral blood directly after human liver transplantation, and low levels were sustained in patients who experienced acute rejection episodes, whereas a relative recovery of this subset was observed in patients with stable allograft function.
In summary, cells with regulatory function do seem to participate in both the induction and the maintenance phase of liver transplant tolerance. Although the recipient CD4 þ CD25 þ Treg subset seems to be critical in the induction phase, other types of regulatory cells of undetermined phenotype and mode of action might function during the maintenance phase. 
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CONCLUSIONS: A UNIFIED MODEL OF LIVER TRANSPLANT TOLERANCE
The first report of spontaneous antigen-specific liver transplant tolerance by Calne in 1969 opened the quest for the identification of an underlying mechanism that might be exploited to induce tolerance to all human solid organ transplants. Meanwhile, over some 35 years, explanations of this unique property have flourished, but none satisfactorily explain all of the associated immunological findings. Probably none of the postulated pathways functions in isolation to establish hepatic allograft tolerance in the absence of immunosuppression, but instead several of these mechanisms act in concert (Fig. 3) .
The balance between rejection and acceptance of liver grafts seems very delicate and can be readily influenced by the handling of the graft, procedures such as donor irradiation, or depletion or infusion of specific cell subsets. It is also evident that the delicate balance is affected by the recipient's prior exposure to pathogens that might have generated donor cross-reactive memory responses capable of mediating rejection and also by genetic influences in the recipient. In this context, it is important to attempt a separation of processes that are responsible for the induction and those important for the maintenance of allograft tolerance.
The Induction Phase of Liver Transplant Tolerance One of the major properties of the liver is that it is extremely resilient to injury because of its marked regenerative capacity, a property that might successfully counteract ongoing liver damage mediated by low-affinity T cells and alloantibodies. Damage of liver tissue, whether due to IRI or to immune responses, is associated with the spillage of donor antigens including soluble MHC molecules that might directly bind and therefore protect liver tissue from preexisting alloreactive antibodies. This might explain why liver allografts can sometimes be transplanted across ABO blood groups and why a positive preoperative cross-match can turn negative within a few hours after transplantation without causing major damage. 67, [74] [75] [76] But neither released donor antigens/MHC molecules nor the regenerative capacity of the liver can explain why some individuals are able to arrest and even completely resolve an initial T cell infiltrate in the liver.
Most studies agree that the induction of spontaneous liver acceptance is an active process associated with apoptosis of alloreactive T cells in both the graft and the spleen. 115, 176 The activation events preceding this apoptosis are yet to be characterized, but they may well differ according to T cell subsets, naïve, effector, and memory, and do occur rapidly within the first few hours following transplantation in both liver and SLT.
We propose that in the human liver transplant, naïve recipient alloreactive CD8 þ T cells circulating from the blood are retained in the liver within the first few hours and activated in situ by the direct antigen presentation pathway; such a process could lead to their death by neglect as suggested by transgenic mouse models. 170 Considering that the liver receives 20% of the cardiac output, the trafficking naïve T cell population may be rendered tolerogenic through this pathway. There is also evidence that recently activated CD8 þ T cells that recognize antigen in the liver undergo apoptosis through other mechanisms. 5 Thus, we propose that these two early events purge the host repertoire of a significant proportion of high-affinity graft-reactive T cells that will condition the rest of the response. Whether low-affinity memory CD8 þ and CD4 þ T cells are spared is unclear at this stage. The unique architecture of the liver might be critical for these events to occur, and this model is consistent with the observation that both parenchyma and bone marrow-derived cells resident in the liver play a role in liver tolerance. 167 Whereas some donor T cells are likely to be retained in the liver, some passenger leukocytes are able to migrate into SLT, where they can activate host naïve and T CM T cells. Among these leukocytes, donor DCs with tolerogenic properties might activate T cells by the direct presentation pathway and secrete cytokines that downregulate the response. Other donor leukocyte subsets might also activate alloreactive host T cells and induce clonal exhaustion or death by neglect. 107 Experimentally, depletion of naturally occurring recipient CD4 þ CD25 þ Tregs prior to transplantation was also able to convert liver tolerance into rejection, suggesting their role in inducing tolerance. However, depletion of this cell subset at later time points had no effect, indicating just a temporary regulatory function of these cells during the induction phase.
The Maintenance Phase of Liver Transplant Tolerance Although tolerance might be induced early after transplantation, the transplanted liver permanently faces rejection by hazardous preexisting host T cells that have not been deleted during the induction phase; such hazardous T cells may be new alloreactive thymic emigrants or even cross-reactive recipient T cells activated by host DCs through the indirect presentation pathway. Furthermore, T cells activated and expanded during infections might cross-react with donor MHC/peptide complexes and cause allograft rejection. Thus, some mechanisms proposed to be responsible for spontaneous acceptance of liver transplants might well be required for maintaining tolerance rather than inducing it.
One of these mechanisms is microchimerism. Although it is an attractive idea, direct evidence is still lacking that long-term microchimerism serves to sustain tolerance in solid organ transplantation. Only stem cells (and cancer cells) possess the capacity of indefinite replication and survival, so that long-term microchimerism is more likely induced and maintained by donor hematopoietic stem cells. Such cells can differentiate into donor DCs, which might induce central deletion, or differentiate into hematopoietic cells that would simply provide a constant source of donor peptides. Parenchymal cells releasing soluble MHC molecules and other proteins might represent an important source of donor peptides and explain their role in tolerance as previously suggested. 122, 167 Although these events take place, it is likely that the maintenance of tolerance is relayed by the generation of Tregs. Most studies agree that these cells require at least 30 days for their generation. 196, 197 These cells are phenotypically distinct from CD4 þ CD25 þ Tregs, 198 and both the location and the mode of their suppressive function need to be further established.
As a final summary, there are several properties that set liver transplants apart from other solid organ transplants, and these might explain spontaneous acceptance. First, the liver is characterized by a spectacular regenerative capacity and secretion of high levels of soluble MHC class I molecules that might protect it from damage due to preexisting alloantibodies early after transplantation. During this time, the liver graft might interfere with the activation of both donor-specific naïve and effector T cells. Here, several mechanisms might occur simultaneously; some events occur in the SLT, and others happen within the liver graft itself. Although the transplanted liver seems able to induce peripheral deletion of naïve and effector T cells, so far there is no evidence that memory T cells are affected. Therefore, finding treatments that favor primary activation of allogeneic T cells in the liver and simultaneously inactivate preexisting memory and effector T cells that cross-react against the graft will represent a major challenge for future therapies in transplantation of the liver and other solid organs.
